BioSpace News Archive

Eisai Co., Ltd. announced that the company will have a total of 34 posters, including the latest data on its in-house discovered and developed anti-seizure medication FYCOMPA® CIII, at the 76th American Epilepsy Society Annual Meeting, to be held in Nashville, Tennessee and virtually from December 2-6, 2022.

According to Nova one advisor, the global Biomaterials market size is expected to hit around USD 488.9 billion by 2030 from valued at USD 135.8 billion in 2021 and growing at a CAGR of 15.8% from 2022 to 2030.

Awakn’s Nordic expansion begins with new Awakn Clinics Oslo

According to Vision Research Reports, the global pyrogen testing market size surpassed at US$ 0.94 billion in 2021 and is expected to grow at a CAGR of 12.5% from 2022 to 2030.

According to Vantage Market Research latest qualitative research the Global Oncology Market is valued at USD 283.5 Billion in 2021.

Third-party research conducted by leading U.S. academic institutions published in a peer reviewed journal Frontiers in Immunology shows a favorable safety profile for intranasally administered foralumab and immunological activity in humans.

Bright Minds Biosciences today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022.

Ryvu Therapeutics today announced third quarter 2022 financial results and provided a corporate update.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the successful completion of its Good Laboratory Practice (“GLP”) studies on the AccuVAC-PT007 vaccine candidate specifically designed to target cervical cancer.

The global vitamin deficiency treatment market size was valued at US$ 5.86 billion in 2021 and is projected to expand at a CAGR of 6.6% from 2022 to 2030.